A Prescription Drug User Fee Act target date of June 23 ... unresectable or metastatic CRC were randomly assigned to receive nivolumab monotherapy, nivolumab plus ipilimumab, or investigator ...

CEL-SCI (CVM) announced that a third-party study published on March 6 in JAMA Oncology provided data that support Multikine’s use as a ...

The study enrolled 64 patients with treatment-naïve metastatic melanoma between March 2017 and July 2019. Participants ...

nivolumab plus ipilimumab and nivolumab plus relatlimab. Both immunotherapy combinations appeared to perform equally well.

Skin cancer advanced clinical practitioners ensure continuity of care for patients with malignant melanoma and other advanced ...

Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of Head and Neck Patients.

SHANGHAI, China I March 23, 2025 I Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, ...

Burchfield, MD, and other participants discussed their experiences with the frontline combination regimens for advanced renal ...

Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

The EC approves BMY's combination of Opdivo and Yervoy for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma.

Cretostimogene treatment shows best-in-class durability of response for BCG-unresponsive non-muscle invasive bladder cancer ...